Drugs that contain Glycopyrrolate; Indacaterol Maleate
1. Drug name - UTIBRON
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 years from now) | |
| CN1156451C | NOVARTIS | Adrenoreceptor Agonist |
Jun, 2020
(2 years ago) | |
| CN1353692A | NOVARTIS | Adrenoreceptor Agonist |
Jun, 2020
(2 years ago) | |
| IN222346B | NOVARTIS | Beta2-Adrenoceptor Agonists |
Jun, 2020
(2 years ago) | |
| IN200101673P4 | NOVARTIS | Beta 2-Adrenoceptor Agonists |
Jun, 2020
(2 years ago) | |
| EP2332915A1 | NOVARTIS | Beta2-Adrenoceptor Agonists |
Jun, 2020
(2 years ago) | |
| EP2332915B1 | NOVARTIS | Beta2-Adrenoceptor Agonists |
Jun, 2020
(2 years ago) | |
| EP1183240A1 | NOVARTIS | Beta2-Adrenoceptor Agonists |
Nov, 2024
(2 years from now) | |
| EP1183240B1 | NOVARTIS | Beta2-Adrenoceptor Agonists |
Nov, 2024
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(6 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(6 years from now) | |
Treatment: NA
Dosage: POWDER;INHALATION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 15.6MCG/INH;27.5MCG/INH | POWDER;INHALATION | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.